Tenofovir Diastereomer Mixture

Stability indicating RP-​HPLC method development and validation for the simultaneous estimation of darunavir, cobicistat, emtricitabine and tenofovir alafenamide in bulk and pharmaceutical formulation
By Parameswari, S. Angala; Ankinapalli, Ajay Kumar Reddy; Tsegaye, Tesfaye; Alagusundaram, M.
From International Journal of Pharmaceutical Sciences and Research (2021), 12(6), 3216-3224
 
Stability-​indicating high-​performance thin-​layer chromatography method for the simultaneous estimation of emtricitabine and tenofovir alafenamide fumarate
By Kashid, Arun M.; Kadam, Rohini R.
From Journal of Planar Chromatography--Modern TLC (2021), Ahead of Print
 
Method development and validation for multi-​component analysis of lamivudine & tenofovir disoproxil fumarate in bulk drug by UV-​visible spectrophotometer & RP-​HPLC
By Sharma, Shweta; Ankalgi, Amar Deep; Kaushal, Pooja; Ashawat, M. S.
From Journal of Applied Pharmaceutical Research (2020), 8(4), 70-76

Tenofovir Diastereomer Mixture is chemically (((R)-((((R)-1-(6-Amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(methoxy)phosphoryl)oxy)methyl isopropyl carbonate compound with (((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(methoxy)phosphoryl)oxy)methyl isopropyl carbonate (1:1). Tenofovir Diastereomer Mixture is supplied with detailed characterization data compliant with regulatory guideline. Tenofovir Diastereomer Mixture can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Tenofovir.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.